Randomized, an open controlled trial of memantine in moderate Alzheimer's disease already receiving cholinesterase inhibitors.

Randomized, an open controlled trial of memantine in moderate Alzheimer's disease already receiving cholinesterase inhibitors. - Randomized, an open controlled trial of memantine in moderate Alzheimer's disease already receiving cholinesterase inhibitors.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011222

Enrollment

Registered

2013-07-18

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Interventions donepezil + memantine 20mg/day, 52week Interventions galantamine + memantine 20mg/day, 52week Interventions rivastigmine + memantine 20mg/day, 52week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis; Diagnostic and Statistical Manual of Mental Disorders 4 Text Revision or National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. Outpatient or inpatient.

Exclusion criteria

Exclusion criteria: cardiac failure, epilepsia,creatinine clearance 30>, other serious physical disease.

Design outcomes

Primary

Measure	Time frame
Mini-Mental State Examination	—

Countries

Japan

Contacts

Public ContactShinji Matsunaga

Fujita Health University School of Medicine Department of Psychiatry

shinjim@fujita-hu.ac.jp0562939250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Randomized, an open controlled trial of memantine in moderate Alzheimer&#39;s disease already receiving cholinesterase inhibitors.